Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With a Meningococcal C-Tetanus Toxoid Conjugate Vaccine and Other Routine Pediatric Vaccinations in Spain

The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccinations in Spain.

Inclusion Criteria:

• Healthy 2-month-old infants
• Available for the entire study period

Exclusion criteria:

• Previous vaccination with any vaccine before the start of the study
• Known contraindication to vaccination